Blue Jet Healthcare Ltd vs Vaishali Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Blue Jet Healthcare Ltd is ₹ 488.4 as of 06 May 15:30 . The P/E Ratio of Blue Jet Healthcare Ltd is 0 as of March 2021 .The P/E Ratio of Vaishali Pharma Ltd is 0 as of March 2021 . The Market Cap of Blue Jet Healthcare Ltd is ₹ 0 crore as of March 2021 .The Market Cap of Vaishali Pharma Ltd is ₹ 0 crore as of March 2021 . The Revenue of Blue Jet Healthcare Ltd is ₹ 0 crore as of Jun '25 .The Revenue of Vaishali Pharma Ltd is ₹ 24.59 crore as of Jun '25 . The EBITDA of Blue Jet Healthcare Ltd is ₹ 0 crore as of Jun '25 .The EBITDA of Vaishali Pharma Ltd is ₹ 2.21 crore as of Jun '25 . The Net Profit of Blue Jet Healthcare Ltd is ₹ 0 crore as of Jun '25 .The Net Profit of Vaishali Pharma Ltd is ₹ 1.28 crore as of Jun '25 . The Dividend Payout of Blue Jet Healthcare Ltd changed from 10.59 % on March 2024 to 6.82 % on March 2025 . This represents a CAGR of -19.75% over 2 yearsThe Dividend Payout of Vaishali Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Blue Jet Healthcare Ltd

Blue Jet Healthcare Limited was originally incorporated as Jet Chemicals Private Limited,' at Mumbai, dated December 7, 1968.
The Company name was changed to Blue Jet Healthcare Private Limited', and a fresh Certificate of Incorporation dated December 30, 2020, was issued by the Registrar of Companies, Mumbai.
Subsequently, the status got converted into a Limited Company and its name was changed to Blue Jet Healthcare Limited' on May 18, 2022. The Company is a global, science-led, pharmaceutical company evolved as strategic partner for Collaboration, Development & Manufacturing of Advance Pharmaceutical Intermediates and API. It operate into 3 product categories, contrast media intermediates, high- intensity sweeteners, and pharma intermediates and active pharmaceutical ingredients (APIs).

About Vaishali Pharma Ltd

Vaishali Pharma Limited was originally incorporated as a Private Limited Company with the name 'Vaishali Pharma Private Limited' on 25th, April 2008.
On July 01, 2008 the Company acquired the business of proprietorship concerns of its Promoter Mr. Atul Vasani viz.
M/s.
Vaishali Pharmachem through Business Assignment agreement.
Consequently, the business of said Proprietorship Firm merged into Vaishali Pharma Private Limited.

FAQs for the comparison of Blue Jet Healthcare Ltd and Vaishali Pharma Ltd

Which company has a larger market capitalization, Blue Jet Healthcare Ltd or Vaishali Pharma Ltd?

Market cap of Blue Jet Healthcare Ltd is 8,472 Cr while Market cap of Vaishali Pharma Ltd is 98 Cr

What are the key factors driving the stock performance of Blue Jet Healthcare Ltd and Vaishali Pharma Ltd?

The stock performance of Blue Jet Healthcare Ltd and Vaishali Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Blue Jet Healthcare Ltd and Vaishali Pharma Ltd?

As of May 6, 2026, the Blue Jet Healthcare Ltd stock price is INR ₹488.4. On the other hand, Vaishali Pharma Ltd stock price is INR ₹7.58.

How do dividend payouts of Blue Jet Healthcare Ltd and Vaishali Pharma Ltd compare?

To compare the dividend payouts of Blue Jet Healthcare Ltd and Vaishali Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.